GSK signs AI pact with Ochre to pinpoint source of liver diseases

GSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease.

The new partnership, announced Wednesday morning, will see GSK access Ochre’s computational biology, cellular and perfused human organ platforms to generate human liver data sets that can be used to better understand the biology of the liver.